Coronavirus (COVID-19)Health

Celebrate Cautiously: Pfizer/BioNTech Covid-19 Vaccine

A 90% success rate for Pfizer’s Covid-19 is amazing.

A news statement was issued Monday, November, stating PFIZER and partner BioNTech’s Covid-19 vaccine was 90% successful in large scale trials. As a result, global markets surged, and Pfizer’s stocks jumped up 9% or more. Pfizer/BioNTech has the first Covid-19 tested vaccine in the United States to issue late-stage data. The report shows the early analysis of those who received two vaccines at three weeks apart had 90% fewer cases of indicative Covid-19 than participants who were given a control substance.

The interim analysis information comes from an outside monitoring board that investigated 94 infections that occurred in a study with 44,000 participants. Some participants received the vaccine, and it is suspected that the contamination came from those who received placebos.

Read More »

Related Articles

Back to top button


Get a daily email of trending news and updates. Be the first to see top stories and events.